Protein biomarkers in cystic fibrosis research: Where next?

Genome Medicine

Volumn 2, Issue 12, 2010, Pages

  Pattison, Sally H ^a   Elborn, J Stuart ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS AFFECTING PROTEIN METABOLISM; ATALUREN; BIOLOGICAL MARKER; CHEMOKINE RECEPTOR CXCR2 ANTAGONIST; DIGITOXIN; DOXYCYCLINE; GELATINASE B; HEAT SHOCK PROTEIN 60; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G; INTERLEUKIN 6; INTERLEUKIN 8; MUTANT PROTEIN; PIOGLITAZONE; SB 656933; SILDENAFIL; SMALL INTERFERING RNA; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG; VX 770; VX 809;

ANTIINFLAMMATORY ACTIVITY; BACTERIAL VIRULENCE; CHRONIC INFLAMMATION; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); CYSTIC FIBROSIS; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG MECHANISM; DRUG SAFETY; EARLY DIAGNOSIS; FUNCTIONAL PROTEOMICS; GENE TARGETING; HIGH THROUGHPUT SCREENING; HUMAN; LUNG DISEASE; LUNG INFECTION; MITOCHONDRION; MOLECULAR DYNAMICS; MONITORING; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; OXIDATIVE STRESS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN HOMEOSTASIS; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; PROTEIN TARGETING; PSEUDOMONAS AERUGINOSA; REVIEW;

EID: 78751683937     PISSN: None     EISSN: 1756994X     Source Type: Journal    
DOI: 10.1186/gm209     Document Type: Review

References (58)

1. Cystic Fibrosis Mutation Database. , http://www.genet.sickkids.on.ca/cftr
2. Ratjen FA. Cystic fibrosis: pathogenesis and future treatment strategies. Respir Care 2009, 54:595-605. 10.4187/aarc0427, 19393104.
3. Cystic Fibrosis Genetic Analysis Consortium Worldwide survey of the delta F508 mutation - report from the cystic fibrosis genetic analysis consortium. Am J Hum Genet 1990, 47:354-359. 1683705, 2378364, Cystic Fibrosis Genetic Analysis Consortium.
4. Boucher R. Evidence for airway surface dehydration as the initiating event in CF airway disease. J Intern Med 2007, 261:5-16. 10.1111/j.1365-2796.2006.01744.x, 17222164.
5. Riordan J, Rommens J, Kerem B, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok S, Plavsic N, Chou J. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989, 245:1066-1073. 10.1126/science.2475911, 2475911.
6. Cystic Fibrosis Foundation. , http://www.cff.org
7. The UK Cystic Fibrosis Gene Therapy Consortium. , http://www.cfgenetherapy.org.uk
8. ClinicalTrials.gov. , http://www.clinicaltrials.gov
9. Kerem E, Hirawat S, Armoni S, Yaakov Y, Shoseyov D, Cohen M, Nissim-Rafinia M, Blau H, Rivlin J, Aviram M, Elfring GL, Northcutt VJ, Miller LL, Kerem B, Wilschanski M. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 2008, 372:719-727. 10.1016/S0140-6736(08)61168-X, 18722008.
10. Lubamba B, Lecourt H, Lebacq J, Lebecque P, De Jonge H, Wallemacq P, Leal T. Preclinical evidence that sildenafil and vardenafil activate chloride transport in cystic fibrosis. Am J Respir Crit Care Med 2008, 177:506-515. 10.1164/rccm.200703-344OC, 18006891.
11. Srivastava M, Eidelman O, Zhang J, Paweletz C, Caohuy H, Yang Q, Jacobson KA, Heldman E, Huang W, Jozwik C, Pollard BS, Pollard HB. Digitoxin mimics gene therapy with CFTR and suppresses hypersecretion of IL-8 from cystic fibrosis lung epithelial cells. Proc Natl Acad Sci USA 101:7693-7698. 10.1073/pnas.0402030101, 419668, 15136726.
12. Ollero M, Junaidi O, Zaman MM, Tzameli I, Ferrando AA, Andersson C, Blanco PG, Bialecki E, Freedman SD. Decreased expression of peroxisome proliferator activated receptor γ in CFTR-/- mice. J Cell Physiol 2004, 200:235-244. 10.1002/jcp.20020, 15174093.
13. Perez A, van Heeckeren AM, Nichols D, Gupta S, Eastman JF, Davis PB. Peroxisome proliferator-activated receptor-γ in cystic fibrosis lung epithelium. Am J Physiol Lung Cell Mol Physiol 2008, 295:L303-L313. 10.1152/ajplung.90276.2008, 2519842, 18556801.
14. Sagel S, Kapsner R, Osberg L. Induced sputum matrix metalloproteinase-9 correlates with lung function and airway inflammation in children with cystic fibrosis. Pediatr Pulmonol 2005, 39:224-232. 10.1002/ppul.20165, 15635615.
15. Mayer-Hamblett N, Aitken ML, Accurso FJ, Kronmal RA, Konstan MW, Burns JL, Sagel SD, Ramsey BW. Association between pulmonary function and sputum biomarkers in cystic fibrosis. Am J Respir Crit Care Med 2007, 175:822-828. 10.1164/rccm.200609-1354OC, 2720115, 17234902.
16. Griese M, von Bredow C, Birrer P. Reduced proteolysis of surfactant protein A and changes of the bronchoalveolar lavage fluid proteome by inhaled alpha 1-protease inhibitor in cystic fibrosis. Electrophoresis 2001, 22:165-171. 10.1002/1522-2683(200101)22:1<165::AID-ELPS165>3.0.CO;2-H, 11197168.
17. Downey D, Martin S, Dempster M, Moore J, Keogan M, Starcher B, Edgar J, Bilton D, Elborn J. The relationship of clinical and inflammatory markers to outcome in stable patients with cystic fibrosis. Pediatr Pulmonol 2007, 42:216-220. 10.1002/ppul.20553, 17238189.
18. Rowe SM, Jackson PL, Liu G, Hardison M, Livraghi A, Solomon GM, McQuaid DB, Noerager BD, Gaggar A, Clancy JP, O'Neal W, Sorscher EJ, Abraham E, Blalock JE. Potential role of high-mobility group box 1 in cystic fibrosis airway disease. Am J Respir Crit Care Med 2008, 178:822-831. 10.1164/rccm.200712-1894OC, 2566793, 18658107.
19. Sagel SD, Chmiel JF, Konstan MW. Sputum biomarkers of inflammation in cystic fibrosis lung disease. Proc Am Thorac Soc 2007, 4:406-417. 10.1513/pats.200703-044BR, 2647605, 17652508.
20. Gharib S, Vaisar T, Aitken M, Park D, Heinecke J, Fu X. Mapping the lung proteome in cystic fibrosis. J Proteome Res 2009, 8:3020-3029. 10.1021/pr900093j, 19354268.
21. MacGregor G, Gray RD, Hilliard TN, Imrie M, Boyd AC, Alton EWFW, Bush A, Davies JC, Innes JA, Porteous DJ, Greening AP. Biomarkers for cystic fibrosis lung disease: application of SELDI-TOF mass spectrometry to BAL fluid. J Cyst Fibros 2008, 7:352-358. 10.1016/j.jcf.2007.12.005, 18243068.
22. Gray RD, MacGregor G, Noble D, Imrie M, Dewar M, Boyd AC, Innes JA, Porteous DJ, Greening AP. Sputum proteomics in inflammatory and suppurative respiratory diseases. Am J Respir Crit Care Med 2008, 178:444-452. 10.1164/rccm.200703-409OC, 2643212, 18565957.
23. Frischer T, Myung J, Maurer G, Eichler I, Szepfalusi Z, Lubec G. Possible dysregulation of chaperon and metabolic proteins in cystic fibrosis bronchial tissue. Proteomics 2006, 6:3381-3388. 10.1002/pmic.200500487, 16637013.
24. Srivastava M, Eidelman O, Jozwik C, Paweletz C, Huang W, Zeitlin PL, Pollard HB. Serum proteomic signature for cystic fibrosis using an antibody microarray platform. Mol Genet Metab 2006, 87:303-310. 10.1016/j.ymgme.2005.10.021, 16406648.
25. Pollard HB, Eidelman O, Jozwik C, Huang W, Srivastava M, Ji XD, McGowan B, Norris CF, Todo T, Darling T, Mogayzel PJ, Zeitlin PL, Wright J, Guggino WB, Metcalf E, Driscoll WJ, Mueller G, Paweletz C, Jacobowitz DM. De novo biosynthetic profiling of high abundance proteins in cystic fibrosis lung epithelial cells. Mol Cell Proteomics 2006, 5:1628-1637. 10.1074/mcp.M600091-MCP200, 16829594.
26. Roxo-Rosa M, da Costa G, Luider T, Scholte B, Coelho A, Amaral M, Penque D. Proteomic analysis of nasal cells from cystic fibrosis patients and non-cystic fibrosis control individuals: search for novel biomarkers of cystic fibrosis lung disease. Proteomics 2006, 6:2314-2325. 10.1002/pmic.200500273, 16518875.
27. Carvalho-Oliveira I, Charro N, Aarbiou J, Buijs-Offerman R, Wilke M, Schettgen T, Kraus T, Titulaer M, Burgers P, Luider T, Penque D, Scholte B. Proteomic analysis of naphthalene-induced airway epithelial injury and repair in a cystic fibrosis mouse model. J Proteome Res 2009, 8:3606-3616. 10.1021/pr900021m, 19438287.
28. Brouillard F, Bensalem N, Hinzpeter A, Tondelier D, Trudel S, Gruber AD, Ollero M, Edelman A. Blue native/SDS-PAGE analysis reveals reduced expression of the mClCA3 protein in cystic fibrosis knock-out mice. Mol Cell Proteomics 2005, 4:1762-1775. 10.1074/mcp.M500098-MCP200, 16099848.
29. Bensalem N, Ventura AP, Vallée B, Lipecka J, Tondelier D, Davezac N, Santos AD, Perretti M, Fajac A, Sermet-Gaudelus I, Renouil M, Lesure J, Halgand F, Laprévote O, Edelman A. Down-regulation of the anti-inflammatory protein annexin A1 in cystic fibrosis knock-out mice and patients. Mol Cell Proteomics 2005, 4:1591-1601. 10.1074/mcp.M500019-MCP200, 16014420.
30. Sloane AJ, Lindner RA, Prasad SS, Sebastian LT, Pedersen SK, Robinson M, Bye PT, Nielson DW, Harry JL. Proteomic analysis of sputum from adults and children with cystic fibrosis and from control subjects. Am J Respir Crit Care Med 2005, 172:1416-1426. 10.1164/rccm.200409-1215OC, 16166615.
31. McMorran BJ, Ouvry Patat SA, Carlin JB, Grimwood K, Jones A, Armstrong DS, Galati JC, Cooper PJ, Byrnes CA, Francis PW, Robertson CF, Hume DA, Borchers CH, Wainwright CE, Wainwright BJ. Novel neutrophil-derived proteins in bronchoalveolar lavage fluid indicate an exaggerated inflammatory response in pediatric cystic fibrosis patients. Clin Chem 2007, 53:1782-1791. 10.1373/clinchem.2007.087650, 17702859.
32. Woods DE, Cantin A, Cooley J, Kenney DM, Remold-O'Donnell E. Aerosol treatment with MNEI suppresses bacterial proliferation in a model of chronic Pseudomonas aeruginosa lung infection. Pediatr Pulmonol 2005, 39:141-149. 10.1002/ppul.20167, 15633200.
33. Roum JH, Buhl R, McElvaney NG, Borok Z, Crystal RG. Systemic deficiency of glutathione in cystic fibrosis. J Appl Physiol 1993, 75:2419-2424.
34. Chen J, Kinter M, Shank S, Cotton C, Kelley T, Ziady A. Dysfunction of Nrf-2 in CF epithelia leads to excess intracellular H2O2 and inflammatory cytokine production. PLoS One 2008, 3:e3367. 10.1371/journal.pone.0003367, 2563038, 18846238.
35. Bai Y, Galetskiy D, Damoc E, Paschen C, Liu Z, Griese M, Liu S, Przybylsk M. High resolution mass spectrometric alveolar proteomics: identification of surfactant protein SP-A and SP-D modifications in proteinosis and cystic fibrosis patients. Proteomics 2004, 4:2300-2309. 10.1002/pmic.200400855, 15274124.
36. Schulz BL, Sloane AJ, Robinson LJ, Prasad SS, Lindner RA, Robinson M, Bye PT, Nielson DW, Harry JL, Packer NH, Karlsson NG. Glycosylation of sputum mucins is altered in cystic fibrosis patients. Glycobiology 2007, 17:698-712. 10.1093/glycob/cwm036, 17392389.
37. Goldstein RF, Niraj A, Sanderson TP, Wilson LS, Rab A, Kim H, Bebok Z, Collawn JF. VCP/p97 AAA-ATPase does not interact with the endogenous wild-type cystic fibrosis transmembrane conductance regulator. Am J Respir Cell Mol Biol 2007, 36:706-714. 10.1165/rcmb.2006-0365OC, 1899338, 17272822.
38. Gomes-Alves P, Neves S, Coelho A, Penque D. Low temperature restoring effect on F508del-CFTR misprocessing: a proteomic approach. J Proteomics 2009, 73:218-230. 10.1016/j.jprot.2009.09.001, 19775599.
39. Singh OV, Pollard HB, Zeitlin PL. Chemical rescue of ΔF508-CFTR mimics genetic repair in cystic fibrosis bronchial epithelial cells. Mol Cell Proteomics 2008, 7:1099-1110. 10.1074/mcp.M700303-MCP200, 2424193, 18285607.
40. Wang X, Venable J, LaPointe P, Hutt D, Koulov A, Coppinger J, Gurkan C, Kellner W, Matteson J, Plutner H, Riordan J, Kelly J, Yates J, Balch W. Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis. Cell 2006, 127:803-815. 10.1016/j.cell.2006.09.043, 17110338.
41. Thelin W, Che Y, Gentzsch M, Kreda S, Sallee J, Scarlett C, Borchers C, Jacobson K, Stutts M, Milgram S. Direct interaction with filamins modulates the stability and plasma membrane expression of CFTR. J Clin Invest 2007, 117:364-374. 10.1172/JCI30376, 1765518, 17235394.
42. Pedersen SK, Sloane AJ, Prasad SS, Sebastian LT, Lindner RA, Hsu M, Robinson M, Bye PT, Weinberger RP, Harry JL. An immunoproteomic approach for identification of clinical biomarkers for monitoring disease. Mol Cell Proteomics 2005, 4:1052-1060. 10.1074/mcp.M400175-MCP200, 15901828.
43. Rao AR, Laxova A, Farrell PM, Barbieri JT. Proteomic identification of OprL as a seromarker for initial diagnosis of Pseudomonas aeruginosa infection of patients with cystic fibrosis. J Clin Microbiol 2009, 47:2483-2488. 10.1128/JCM.02182-08, 2725635, 19553571.
44. Montor WR, Huang J, Hu Y, Hainsworth E, Lynch S, Kronish J, Ordonez CL, Logvinenko T, Lory S, LaBaer J. Genome-wide study of Pseudomonas aeruginosa outer membrane protein immunogenicity using self-assembling protein microarrays. Infect Immun 2009, 77:4877-4886. 10.1128/IAI.00698-09, 2772540, 19737893.
45. Vanlaere E, Sergeant K, Dawyndt P, Kallow W, Erhard M, Sutton H, Dare D, Devreese B, Samyn B, Vandamme P. Matrix-assisted laser desorption ionisation-time-of-flight mass spectrometry of intact cells allows rapid identification of Burkholderia cepacia complex. J Microbiol Methods 2008, 75:279-286. 10.1016/j.mimet.2008.06.016, 18627778.
46. Sriramulu D, Nimtz M, Romling U. Proteome analysis reveals adaptation of Pseudomonas aeruginosa to the cystic fibrosis lung environment. Proteomics 2005, 5:3712-3721. 10.1002/pmic.200401227, 16097035.
47. Malhotra S, Silo-Suh LA, Mathee K, Ohman DE. Proteome analysis of the effect of mucoid conversion on global protein expression in Pseudomonas aeruginosa strain PAO1 shows induction of the disulfide bond isomerase, DsbA. J Bacteriol 2000, 182:6999-7006. 10.1128/JB.182.24.6999-7006.2000, 94826, 11092861.
48. Platt MD, Schurr MJ, Sauer K, Vazquez G, Kukavica-Ibrulj I, Potvin E, Levesque RC, Fedynak A, Brinkman FSL, Schurr J, Hwang S, Lau GW, Limbach PA, Rowe JJ, Lieberman MA, Barraud N, Webb J, Kjelleberg S, Hunt DF, Hassett DJ. Proteomic, microarray, and signature-tagged mutagenesis analyses of anaerobic Pseudomonas aeruginosa at pH 6.5, likely representing chronic, late-stage cystic fibrosis airway conditions. J Bacteriol 2008, 190:2739-2758. 10.1128/JB.01683-07, 2293228, 18203836.
49. Guina T, Purvine SO, Yi EC, Eng J, Goodlett D, Aebersold R. Quantitative proteomic analysis indicates increased synthesis of a quinolone by Pseudomonas aeruginosa isolates from cystic fibrosis airways. Proc Natl Acad Sci USA 2003, 100:2771-2776. 10.1073/pnas.0435846100, 151416, 12601166.
50. Courtney J, Bradley J, McCaughan J, O'Connor T, Shortt C, Bredin C, Bradbury I, Elborn J. Predictors of mortality in adults with cystic fibrosis. Pediatr Pulmonol 2007, 42:525-532. 10.1002/ppul.20619, 17469153.
51. Arevalo-Ferro C, Hentzer M, Reil G, Görg A, Kjelleberg S, Givskov M, Riedel K, Eberl L. Identification of quorum-sensing regulated proteins in the opportunistic pathogen Pseudomonas aeruginosa by proteomics. Environ Microbiol 2003, 5:1350-1369. 10.1046/j.1462-2920.2003.00532.x, 14641579.
52. Riedel K, Arevalo-Ferro C, Reil G, Görg A, Lottspeich F, Eberl L. Analysis of the quorum-sensing regulon of the opportunistic pathogen Burkholderia cepacia H111 by proteomics. Electrophoresis 2003, 24:740-750. 10.1002/elps.200390089, 12601746.
53. Guo Y, Ma S, Grigoryev D, Van Eyk J, Garcia J. 1-DE MS and 2-D LC-MS analysis of the mouse bronchoalveolar lavage proteome. Proteomics 2005, 5:4608-4624. 10.1002/pmic.200500052, 16240291.
54. Welsh M, Rogers C, Stoltz D, Meyerholz D, Prather R. Development of a porcine model of cystic fibrosis. Trans Am Clin Climatol Assoc 2009, 120:149-162. 2744522, 19768173.
55. Stoltz DA, Meyerholz DK, Pezzulo AA, Ramachandran S, Rogan MP, Davis GJ, Hanfland RA, Wohlford-Lenane C, Dohrn CL, Bartlett JA, Nelson GA, Chang EH, Taft PJ, Ludwig PS, Estin M, Hornick EE, Launspach JL, Samuel M, Rokhlina T, Karp PH, Ostedgaard LS, Uc A, Starner TD, Horswill AR, Brogden KA, Prather RS, Richter SS, Shilyansky J, McCray PB, Zabner J, Welsh MJ. Cystic fibrosis pigs develop lung disease and exhibit defective bacterial eradication at birth. Sci Transl Med 2010, 2:29ra31-29ra31. 2889616, 20427821.
56. Kitteringham NR, Jenkins RE, Lane CS, Elliott VL, Park BK. Multiple reaction monitoring for quantitative biomarker analysis in proteomics and metabolomics. J Chromatogr B Analyt Technol Biomed Life Sci 2009, 877:1229-1239. 10.1016/j.jchromb.2008.11.013, 19041286.
57. Makawita S, Diamandis EP. The bottleneck in the cancer biomarker pipeline and protein quantification through mass spectrometry-based approaches: current strategies for candidate verification. Clin Chem 2010, 56:212-222. 10.1373/clinchem.2009.127019, 20007861.
58. Ramsey BW. Outcome measures for development of new therapies in cystic fibrosis: are we making progress and what are the next steps?. Proc Am Thorac Soc 2007, 4:367-369. 10.1513/pats.200703-038BR, 2647601, 17652503.